1380344-62-6

Basic information

• Product Name: 6-(difluoro(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)Methyl)quinoline
• Synonyms: 6-(difluoro(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)Methyl)quinoline
• CAS NO: 1380344-62-6
• Molecular Formula: C18H12F2N8
• Molecular Weight: 378.3382864
• EINECS: -0
• Mol File: 1380344-62-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.57±0.1 g/cm3(Predicted)
• PKA: 3.85±0.10(Predicted)
• CAS DataBase Reference: 6-(difluoro(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)Methyl)quinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(difluoro(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)Methyl)quinoline(1380344-62-6)
• EPA Substance Registry System: 6-(difluoro(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)Methyl)quinoline(1380344-62-6)

Safety Data

• Hazardous Substances Data: 1380344-62-6(Hazardous Substances Data)

Upstream product

• 1380345-36-7 6-(1-methyl-1H-pyrazol-4-yl)-3-(methylthio)-1,2,4-triazine 
• 1380345-35-6 2,2-diethoxy-1-(1-methyl-1H-pyrazol-4-yl)ethanone 
• 37687-18-6 1-(1-methyl-1H-pyrazol-4-yl)-1-ethanone 
• 1380345-38-9 3-hydrazino-6-[(1-methyl)-1H-4-pyrazolyl]-1,2,4-triazine 
• 1093341-40-2 2,2-difluoro-2-(quinolin-6-yl)acetic acid 

Relevant articles and documents

Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor

c-Met/HGF overexpression has been detected in many human malignancies including tumors which are resistant to anticancer therapy. Disrupting the aberrant c-Met/HGF axis has enjoyed significant progress in both preclinical and clinical antitumor campaign. To eliminate the OCH2-related metabolic deficiency of our previously reported triazolotriazine 2, we synthesized a series of CH2-/CF2-linked triazolotriazines and assessed their c-Met activities, leading to the highly potent compound 23 with IC50 values of 0.24 nM of enzymatic activity in c-Met and 0.85 nM of cellular activity in EBC-1 cancer cell line, as well as with complete tumor regression in EBC-1 xenograft mice model at dose of 25 mg/kg via oral administration. Based on its potent anti-proliferative activities and favorable pharmacokinetic properties, 23 has been selected as a drug candidate for preclinical investigation.